Vitamin O ? FDA says no
This article was originally published in The Tan Sheet
Executive Summary
R-Garden, marketer of dietary supplement Vitamin O, has been issued a warning letter regarding numerous violations of the FD&C Act, FDA says. Advertising claims made in mailings, customer testimonials and product descriptions found on the firm's website and in literature classify the supplement as a drug, and therefore would require an NDA, the agency states in the Feb. 8 letter. Questionable claims include testimonials that the oxygen-infused salt water, which can be topically applied or internally ingested, "took a skin cancer off my nose," "help[ed] control angina" and "stops gum infection and pain." R-Garden lacks sufficient scientific evidence to back its claims, the agency says, adding the product does not bear adequate dosing instructions, listed ingredients or recommended daily intakes...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.